Perspectives: It’s Time To Rethink Incentive System For Drug Patents
Read recent commentaries about pharmaceutical issues.
Stat:
Patent Buyouts Are A Bold Way To Spur Health Innovation
The announcement by the Center for Medicare and Medicaid Services that ten drugs will be subject to price negotiation under the Inflation Adjustment Act has unleashed a storm of debate. (James B. Rebitzer and Robert S. Rebitzer, 11/14)
Bloomberg:
Verve Therapeutics Trial: Crispr Offers Hope For A One-Time Cholesterol Drug
The first snippet of data from a human clinical trial suggests the viability of an experimental drug from Verve Therapeutics that uses gene editing to permanently lower cholesterol. It opens the door to a once-fantastical future when people can trade daily lipid-lowering pills for a one-time treatment. (Lisa Jarvis, 11/13)
New England Journal of Medicine:
Biopsies From Healthy Volunteers To Advance Precision Medicine
In response to calls for precision medicine, some clinical and basic scientists have transitioned from evaluating which interventions are safe and effective for a majority of patients to more refined approaches designed to find the right treatment for the right patient at the right time. (Paul L. Kimmel, M.D., and David S,. Wendler, Ph.D., 11/11)
Bloomberg:
Wegovy Clinical Trial: Obesity Drugs Enjoy A Much-Needed Winning Streak
Several critical advances this month will go a long way toward making obesity drugs more widely available to patients: more consistent access, improved affordability and global conviction that these potentially lifelong treatments are worth the cost to the health-care system. (Lisa Jarvis, 11/13)
